Rapport Therapeutics, Inc. (RAPP) Q3 2025 10-Q Quarterly Report
Rapport Therapeutics, Inc. (RAPP) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Rapport Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New clinical hold risk on RAP-219 diabetic peripheral neuropathic pain trial triggered by FDA request for protocol amendments in Q4 2024
- • Updated financial risk: net losses increased to $77.7M for nine months ended Sept 2025 from $58.3M in prior year, cash $513M funding through H2 2029
- • Most impactful regulatory risk: FDA clinical hold on RAP-219 and uncertainty on lifting timing may delay Phase 2 development or halt program
- • Operational risk: RAP-219 Phase 3 trials initiation expected Q3 2026; delays or failures may materially affect near-term development progress
- • Financial risk: up to $116M contingent milestones payable to Janssen under license may require dilution, debt, or use of cash reserves
Get deeper insights on Rapport Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.